TY - JOUR
T1 - Aspirin dosage and thromboxane synthesis in patients with vascular disease
AU - Hart, Robert G.
AU - Leonard, Anne D.
AU - Talbert, Robert L.
AU - Pearce, Lesly A.
AU - Cornell, Elaine
AU - Bovill, Edwin
AU - Feinberg, William M.
PY - 2003/5/1
Y1 - 2003/5/1
N2 - Study Objective. To determine whether urinary 11-dehydrothromboxane B2 (d-TXB2) is a marker of aspirin resistance and define the relationship between aspirin dosage and concentrations of this thromboxane metabolite. Design. Randomized, crossover study. Setting. Two outpatient clinical centers. Patients. Forty-eight patients (mean age 70 yrs) with vascular disease (52% clinical coronary artery disease, 29% cerebrovascular disease, 46% atrial fibrillation). Intervention. Levels of serum thromboxane B2 and d-TXB2 were measured after patients were treated initially with aspirin 325 mg/day for 4 weeks, then again after random assignment to receive aspirin 81, 325, or 1300 mg/day for 4 weeks, and then again after resumption of 325 mg/day for 4 weeks. Measurements and Main Results. During treatment with aspirin 325 mg/day, the mean ± SD serum thromboxane B2 level was 0.9 ± 1.2 ng/ml and median (interquartile range) was 0.4 (0.2-0.9) ng/ml. Mean urinary d-TXB2 was 16 ± 7.9 ng/mmol creatinine, with a median of 15 (9.9-23) ng/mmol creatinine with aspirin 325 mg/day. After 4 weeks of aspirin 81 mg/day, levels of serum thromboxane B2 (p<0.01) and urinary d-TXB2 (p=0.04) were both significantly higher compared with aspirin 325 mg/day; for urinary d-TXB2, the median increase was 3.0 ng/mmol creatinine. After 4 weeks of treatment with aspirin 1300 mg/day, levels of serum thromboxane B2 (p<0.01) and urinary d-TXB2 (p<0.01) were both significantly lower compared with aspirin 325 mg/day; the median decrease in urinary d-TXB2 was 4.4 ng/mmol creatinine. Conclusion. Different aspirin dosages significantly affect serum and urinary markers of thromboxane synthesis.
AB - Study Objective. To determine whether urinary 11-dehydrothromboxane B2 (d-TXB2) is a marker of aspirin resistance and define the relationship between aspirin dosage and concentrations of this thromboxane metabolite. Design. Randomized, crossover study. Setting. Two outpatient clinical centers. Patients. Forty-eight patients (mean age 70 yrs) with vascular disease (52% clinical coronary artery disease, 29% cerebrovascular disease, 46% atrial fibrillation). Intervention. Levels of serum thromboxane B2 and d-TXB2 were measured after patients were treated initially with aspirin 325 mg/day for 4 weeks, then again after random assignment to receive aspirin 81, 325, or 1300 mg/day for 4 weeks, and then again after resumption of 325 mg/day for 4 weeks. Measurements and Main Results. During treatment with aspirin 325 mg/day, the mean ± SD serum thromboxane B2 level was 0.9 ± 1.2 ng/ml and median (interquartile range) was 0.4 (0.2-0.9) ng/ml. Mean urinary d-TXB2 was 16 ± 7.9 ng/mmol creatinine, with a median of 15 (9.9-23) ng/mmol creatinine with aspirin 325 mg/day. After 4 weeks of aspirin 81 mg/day, levels of serum thromboxane B2 (p<0.01) and urinary d-TXB2 (p=0.04) were both significantly higher compared with aspirin 325 mg/day; for urinary d-TXB2, the median increase was 3.0 ng/mmol creatinine. After 4 weeks of treatment with aspirin 1300 mg/day, levels of serum thromboxane B2 (p<0.01) and urinary d-TXB2 (p<0.01) were both significantly lower compared with aspirin 325 mg/day; the median decrease in urinary d-TXB2 was 4.4 ng/mmol creatinine. Conclusion. Different aspirin dosages significantly affect serum and urinary markers of thromboxane synthesis.
UR - http://www.scopus.com/inward/record.url?scp=0038370082&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038370082&partnerID=8YFLogxK
U2 - 10.1592/phco.23.5.579.32206
DO - 10.1592/phco.23.5.579.32206
M3 - Article
C2 - 12741431
AN - SCOPUS:0038370082
VL - 23
SP - 579
EP - 584
JO - Pharmacotherapy
JF - Pharmacotherapy
SN - 0277-0008
IS - 5
ER -